Dacomitinib treatment in the initial 8 weeks
DISEASE PROGRESSION
During the 8 weeks after the start of dacomitinib therapy, nine patients (22.2%) discontinued treatment with dacomitinib. Disease progression was the most common cause (five patients). Among the patients who discontinued dacomitinib within the 8 weeks, the median treatment duration was 22 days (range: 8–52 days) (Table 